Faculty Profile

Erica Woodahl

Erica Woodahl

Associate Professor

Email: erica.woodahl@umontana.edu
Office: Skaggs 480
Personal Website

Personal Summary

Erica Woodahl received a B.S. in Biochemistry at the University of Notre Dame in 1998 and a Ph.D. from the Department of Pharmaceutics at the University of Washington in 2004. She completed a postdoctoral fellowship in clinical pharmacokinetics at the Fred Hutchinson Cancer Research Center in Seattle, Washington. She joined the faculty at the University of Montana in 2007 as an Assistant Professor and was promoted to Associate Professor in 2012.


B.S. Biochemistry; University of Notre Dame (1998)

Ph.D. Pharmaceutics; University of Washington (2004)

Postdoctoral Fellow; Fred Hutchinson Cancer Research Center

Research Interests

The research focus of the Woodahl laboratory is on precision medicine and pharmacogenomics to identify sources of interindividual variability in disease treatment and prevention (e.g. genes, environment, and lifestyle). We are interested in genetic and environmental factors that alter the pharmacokinetics, or ADME (absorption, distribution, metabolism, and elimination), and pharmacodynamics of many therapeutic compounds. 

A major focus of the lab is to study precision medicine and pharmacogenomics with American Indian and Alaska Native populations. This research is part of the Northwest-Alaska Pharmacogenomics Research Network (NWA-PGRN), whose goals are to engage indigenous populations in precision medicine research (1U01GM092676 and P01GM116691). In Montana, we have established a community-academic partnership with the Confederated Salish and Kootenai Tribes living on the Flathead Reservation. This work includes the characterization of genetic variation and environmental factors that predict drug response and toxicity, as well as community-based participatory research to aid in the translation of precision medicine research into the clinic. Precision medicine research has broad utility across many therapeutic areas, with our primary focus on medications for the treatment of cardiovascular diseases and cancer. 

A second area of emphasis in the lab is understanding the mechanisms by which pharmacogenomics alter the function of drug-metabolizing enzymes (e.g. cytochrome P450 drug-metabolizing enzymes) and drug transporters (e.g. ATP-binding cassette transporters) that contribute to drug disposition. We are using a combination of computational, membrane-based, cell-based, and in vivo models to study the functional consequence of genetic variation in drug-metabolizing enzymes and drug transporters. 

Field of Study

Precision Medicine, Pharmacogenomics/Pharmacogenetics, Pharmacokinetics, Drug Metabolism, Drug Transport, Special Populations

Selected Publications

Complete List of Published Work in MyBibliography: http://www.ncbi.nlm.nih.gov/sites/myncbi/erica.woodahl.1/bibliography/45270752/public/?sort=date&direction=ascending


Morales CT, Muzquiz LI, Howlett K, Azure B, Bodnar B, Finley V, Incashola T, Mathias C, Laukes C, Beatty P, Burke W, Pershouse MA, Putnam EA, Trinidad SB, James R, Woodahl EL. Partnership with the Confederated Salish and Kootenai Tribes: Establishing an Advisory Committee for Pharmacogenetic Research. Prog Community Health Partnersh 10:173-83, 2016.

Blunston MA, Yonovitz A, Woodahl EL, Smolensky MH. Gentamicin-Induced Ototoxicity and Nephrotoxicity Vary with Circadian Time of Treatment and Entail Separate Mechanisms. Chronobiol Int 32:1223-32, 2015.

Lacher SE, Skagen K, Veit J, Dalton R, Woodahl ELP-glycoprotein Transport of Neurotoxic PesticidesJ Pharmacol Exp Ther 355:99-107, 2015.

Trahey M Li MJ, Kwon H, Woodahl EL, McClary WD, Atkins WM. Applications of Lipid Nanodiscs for the Study of Membrane Proteins by Surface Plasmon Resonance. Curr Protoc Protein Sci 81:29.13.1-29.13.16, 2015.

Dorfman EH, Trinidad SB, Morales CT, Howlett K, Burke W, Woodahl EL. Pharmacogenomics in Diverse Practice Settings: Implementation Beyond Major Metropolitan Areas. Pharmacogenomics 16:227-37, 2015.

Woodahl EL, Lesko LJ, Hopkins S, Robinson RF, Thummel KE, Burke W. Pharmacogenetic Research in Partnership with American Indian and Alaska Native Communities. Pharmacogenomics 15:1235-41, 2014.

James R, Tsosie R, Sahota P, Parker M, Dillard D, Sylvester I, Lewis J, Klejka J, Muzquiz L, Olsen P, Whitener R, Burke W; Kiana Group*. Exploring pathways to trust: a tribal perspective on data sharing. Genet Med 16:820-6, 2014. *Woodahl EL (member of Kiana Group)

Lacher SE, Gremaud JN, Skagen K, Steed E, Dalton R, Sugden KD, Cardozo-Pelaez F, Sherwin CMT, Woodahl EL. Absence of P-glycoprotein Transport in the Pharmacokinetics and Toxicity of the Herbicide Paraquat. J Pharmacol Exp Ther 348:336-45, 2014.

Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL. Pharmacogenetics in American Indian Populations: Analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes. Pharmacogenet Genomics 23:403-14, 2013.

McCune JS, Woodahl EL, Furlong T, Storer B, Wang J, Heimfeld S, Deeg HJ, O'Donnell PV. A Pilot Pharmacologic Biomarker Study of Busulfan and Fludarabine in Hematopoietic Cell Transplant Recipients. Cancer Chemother Pharmacol 69:263-72, 2012.

Boyer BB, Dillard D, Woodahl EL, Whitener R, Thummel KE, Burke W. Ethical Issues in Developing Pharmacogenetic Research Partnerships with Indigenous Communities. Clin Pharmacol Ther 89:343-5, 2011.

Woodahl EL, Crouthamel MH, Bui T, Shen DD, Ho RJY. MDR1 (ABCB1) G1199A (SER400ASN) Polymorphism Alters Transepithelial Permeability and Sensitivity to Anticancer Agents. Cancer Chemother Pharmacol 64:183-188, 2009.

Woodahl EL, Wang J, Heimfeld S, Sandmaier BM, McCune JS. Intracellular Disposition of Fludarabine Triphosphate in Human Natural Killer Cells. Cancer Chemother Pharmacol 63:959-964, 2009.

Woodahl EL, Wang J, Heimfeld S, Sandmaier BM, O'Donnell PV, Phillips B, Risler L, Blough DK, McCune JS. A Novel Phenotypic Method To Determine Fludarabine Triphosphate Accumulation in T-Lymphocytes from Hematopoietic Cell Transplantation Patients. Cancer Chemother Pharmacol 63:391-401, 2009.

Woodahl EL, Wang J, Heimfeld S, Ren AG, McCune JS. Imatinib Inhibition of Fludarabine Uptake in T-Lymphocytes. Cancer Chemother Pharmacol 62:735-739, 2008.

Woodahl EL, Hingorani SR, Wang J, Guthrie KA, McDonald GB, Batchelder A, Li M, Schoch HG, McCune JS. Pharmacogenomic Associations in ABCB1 and CYP3A5 with Acute Kidney Injury and Chronic Kidney Disease after Myeloablative Hematopoietic Cell Transplantation. Pharmacogenomics J 8:248-255, 2008.

Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJY. MDR1 G1199A Polymorphism Alters Permeability of HIV Protease Inhibitors Across P-glycoprotein-Expressing Epithelial Cells. AIDS 14:1617-1625, 2005.

Woodahl EL and Ho RJY. The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function. Curr Drug Metab 5:11-19, 2004.

Woodahl EL and Ho RJY. Augmentation of Cell-Mediated Immunity to Virus. In: Cellular Drug Delivery: Principle and Practice. Ed: D. Robert Lu and Svein Øie, Humana Press Inc., Totowa, NJ, 2004.

Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJY. Multidrug Resistance Gene G1199A Polymorphism Alters Efflux Transport Activity of P-glycoprotein. J Pharmacol Exp Ther 310:1199-1207, 2004.

Yang Z, Woodahl EL, Wang XY, Bui T, Shen DD, Ho RJY. Semi-Quantitative RT-PCR Method to Estimate Full-Length mRNA Levels of the Multidrug Resistance Gene. Biotechniques 33:196-203, 2002.

Specialized Research Interests

Precision medicine and pharmacogenomics research to understand interindividual variability in disease treatment and preventation.


Graduate Programs

  • Pharmaceutical Sciences and Drug Design
  • Public Health
  • Toxicology

Research Centers

  • Northwest-Alaska Pharmacogenomics Research Network
  • Center for Biomolecular Structure and Dynamics
  • Center for Translational Medicine


  • Affiliate Associate Professor, Department of Pharmaceutics, University of Washington
  • Steering Committee, Rocky Mountain Discussion Group, American Association of Pharmaceutical Scientists
  • Past Chair, Special Populations Community, American Society for Clinical Pharmacology and Therapeutics